Actually, no. That's the thing. Now the model is such that in the U.S. they're thinking about a user fee to evaluate the plans just to administer departments of risk management within regulatory authorities, but the individual studies are paid for by the industry as part of their commitments. Otherwise the drug approval is denied.
On March 11th, 2008. See this statement in context.